Assessment of Safety, Tolerability, Radiation Dosimetry, Imaging Properties of 89Zr-girentuximab in Patients With NMIBC

NCT04897763 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer

Interventions

DRUG: 89Zr-TLX250

Sponsor

Institut Cancerologie de l'Ouest

Collaborators

[object Object]